Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo

Cancer Cell

Volumn 27, Issue 5, 2015, Pages 631-643

  Shirai, Cara Lunn ^a   Ley, James N ^a   White, Brian S ^a,b   Kim, Sanghyun ^a   Tibbitts, Justin ^a   Shao, Jin ^a   Ndonwi, Matthew ^a   Wadugu, Brian ^a   Duncavage, Eric J ^a   Okeyo Owuor, Theresa ^a   Liu, Tuoen ^a   Griffith, Malachi ^b   McGrath, Sean ^b   Magrini, Vincent ^b   Fulton, Robert S ^b   Fronick, Catrina ^b   O'Laughlin, Michelle ^b   Graubert, Timothy A ^c   Walter, Matthew J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PROTEIN; MESSENGER RNA PRECURSOR; RIBOSOME PROTEIN; TRANSCRIPTOME; U2AF1 PROTEIN; UNCLASSIFIED DRUG; MESSENGER RNA; NUCLEAR PROTEIN; RIBONUCLEOPROTEIN; RNA PRECURSOR; U2AF1 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; IN VIVO STUDY; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; RNA PROCESSING; RNA SEQUENCE; RNA SPLICING; ANIMAL; GENETICS; MUTATION; MYELODYSPLASTIC SYNDROME; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ANIMALS; HEMATOPOIESIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE, TRANSGENIC; MUTATION; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; RIBONUCLEOPROTEINS; RNA PRECURSORS; RNA SPLICING; RNA, MESSENGER;

EID: 84929149702     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.04.008     Document Type: Article

References (52)

1. Abdel-Wahab O., Gao J., Adli M., Dey A., Trimarchi T., Chung Y.R., Kuscu C., Hricik T., Ndiaye-Lobry D., Lafave L.M., et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J. Exp. Med. 2013, 210:2641-2659.
2. Anders S., Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010, 11:R106.
3. Anders S., Reyes A., Huber W. Detecting differential usage of exons from RNA-seq data. Genome Res. 2012, 22:2008-2017.
4. Bacher U., Haferlach T., Schnittger S., Zenger M., Meggendorfer M., Jeromin S., Roller A., Grossmann V., Krauth M.T., Alpermann T., et al. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact. Br. J. Haematol. 2014, 164:822-833.
5. Barlow J.L., Drynan L.F., Hewett D.R., Holmes L.R., Lorenzo-Abalde S., Lane A.L., Jolin H.E., Pannell R., Middleton A.J., Wong S.H., et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat. Med. 2010, 16:59-66.
6. Beard C., Hochedlinger K., Plath K., Wutz A., Jaenisch R. Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis 2006, 44:23-28.
7. Bejar R., Stevenson K., Abdel-Wahab O., Galili N., Nilsson B., Garcia-Manero G., Kantarjian H., Raza A., Levine R.L., Neuberg D., Ebert B.L. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 2011, 364:2496-2506.
8. Borel C., Dastugue N., Cances-Lauwers V., Mozziconacci M.J., Prebet T., Vey N., Pigneux A., Lippert E., Visanica S., Legrand F., et al. PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients. Leuk. Res. 2012, 36:1365-1369.
9. Brooks A.N., Choi P.S., de Waal L., Sharifnia T., Imielinski M., Saksena G., Pedamallu C.S., Sivachenko A., Rosenberg M., Chmielecki J., et al. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS ONE 2014, 9:e87361.
10. Brown M.B. Method for Combining Non-Independent, One-Sided Tests of Significance. Biometrics 1975, 31:987-992.
11. Buschbeck M., Uribesalgo I., Wibowo I., Rué P., Martin D., Gutierrez A., Morey L., Guigó R., López-Schier H., Di Croce L. The histone variant macroH2A is an epigenetic regulator of key developmental genes. Nat. Struct. Mol. Biol. 2009, 16:1074-1079.
12. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013, 368:2059-2074. Cancer Genome Atlas Research Network.
13. Catenacci D.V., Schiller G.J. Myelodysplasic syndromes: a comprehensive review. Blood Rev. 2005, 19:301-319.
14. Chan Y.A., Hieter P., Stirling P.C. Mechanisms of genome instability induced by RNA-processing defects. Trends Genet. 2014, 30:245-253.
15. Chia N.Y., Chan Y.S., Feng B., Lu X., Orlov Y.L., Moreau D., Kumar P., Yang L., Jiang J., Lau M.S., et al. A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. Nature 2010, 468:316-320.
16. Damm F., Kosmider O., Gelsi-Boyer V., Renneville A., Carbuccia N., Hidalgo-Curtis C., Della Valle V., Couronné L., Scourzic L., Chesnais V., et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012, 119:3211-3218. Groupe Francophone des Myélodysplasies.
17. Ebert B.L., Pretz J., Bosco J., Chang C.Y., Tamayo P., Galili N., Raza A., Root D.E., Attar E., Ellis S.R., Golub T.R. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008, 451:335-339.
18. Eisfeld A.K., Schwind S., Hoag K.W., Walker C.J., Liyanarachchi S., Patel R., Huang X., Markowitz J., Duan W., Otterson G.A., et al. NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation. Proc. Natl. Acad. Sci. USA 2014, 111:4179-4184.
19. Flicek P., Ahmed I., Amode M.R., Barrell D., Beal K., Brent S., Carvalho-Silva D., Clapham P., Coates G., Fairley S., et al. Ensembl 2013. Nucleic Acids Res. 2013, 41:D48-D55.
20. Gaspar-Maia A., Qadeer Z.A., Hasson D., Ratnakumar K., Leu N.A., Leroy G., Liu S., Costanzi C., Valle-Garcia D., Schaniel C., et al. MacroH2A histone variants act as a barrier upon reprogramming towards pluripotency. Nat. Commun. 2013, 4:1565.
21. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., Ellis B., Gautier L., Ge Y., Gentry J., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5:R80.
22. Graubert T.A., Shen D., Ding L., Okeyo-Owuor T., Lunn C.L., Shao J., Krysiak K., Harris C.C., Koboldt D.C., Larson D.E., et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat. Genet. 2012, 44:53-57.
23. Haferlach T., Nagata Y., Grossmann V., Okuno Y., Bacher U., Nagae G., Schnittger S., Sanada M., Kon A., Alpermann T., et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014, 28:241-247.
24. Hamblin T. Clinical features of MDS. Leuk. Res. 1992, 16:89-93.
25. Ilagan J.O., Ramakrishnan A., Hayes B., Murphy M.E., Zebari A.S., Bradley P., Bradley R.K. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 2014, 25:14-26.
26. Jangi M., Sharp P.A. Building robust transcriptomes with master splicing factors. Cell 2014, 159:487-498.
27. Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., Xie M., Zhang Q., McMichael J.F., Wyczalkowski M.A., et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
28. Kent W.J., Sugnet C.W., Furey T.S., Roskin K.M., Pringle T.H., Zahler A.M., Haussler D. The human genome browser at UCSC. Genome Res. 2002, 12:996-1006.
29. Kim D., Pertea G., Trapnell C., Pimentel H., Kelley R., Salzberg S.L. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013, 14:R36.
30. Ma X. Epidemiology of myelodysplastic syndromes. Am. J. Med. 2012, 125(7, Suppl):S2-S5.
31. Okeyo-Owuor T., White B.S., Chatrikhi R., Mohan D.R., Kim S., Griffith M., Ding L., Ketkar-Kulkarni S., Hundal J., Laird K.M., et al. U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing. Leukemia 2014, 29:909-917.
32. Pang W.W., Pluvinage J.V., Price E.A., Sridhar K., Arber D.A., Greenberg P.L., Schrier S.L., Park C.Y., Weissman I.L. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc. Natl. Acad. Sci. USA 2013, 110:3011-3016.
33. Papaemmanuil E., Cazzola M., Boultwood J., Malcovati L., Vyas P., Bowen D., Pellagatti A., Wainscoat J.S., Hellstrom-Lindberg E., Gambacorti-Passerini C., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 2011, 365:1384-1395. Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium.
34. Papaemmanuil E., Gerstung M., Malcovati L., Tauro S., Gundem G., Van Loo P., Yoon C.J., Ellis P., Wedge D.C., Pellagatti A., et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013, 122:3616-3627. Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium, quiz 3699.
35. Pellagatti A., Hellström-Lindberg E., Giagounidis A., Perry J., Malcovati L., Della Porta M.G., Jädersten M., Killick S., Fidler C., Cazzola M., et al. Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes. Br. J. Haematol. 2008, 142:57-64.
36. Przychodzen B., Jerez A., Guinta K., Sekeres M.A., Padgett R., Maciejewski J.P., Makishima H. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood 2013, 122:999-1006.
37. Raza A., Gezer S., Mundle S., Gao X.Z., Alvi S., Borok R., Rifkin S., Iftikhar A., Shetty V., Parcharidou A., et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995, 86:268-276.
38. Raza A., Mundle S., Iftikhar A., Gregory S., Marcus B., Khan Z., Alvi S., Shetty V., Dameron S., Wright V., et al. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am. J. Hematol. 1995, 48:143-154.
39. Shetty V., Hussaini S., Broady-Robinson L., Allampallam K., Mundle S., Borok R., Broderick E., Mazzoran L., Zorat F., Raza A. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood 2000, 96:1388-1392.
40. Skourti-Stathaki K., Proudfoot N.J. A double-edged sword: R loops as threats to genome integrity and powerful regulators of gene expression. Genes Dev. 2014, 28:1384-1396.
41. Srinivasan R.S., de Erkenez A.C., Hemenway C.S. The mixed lineage leukemia fusion partner AF9 binds specific isoforms of the BCL-6 corepressor. Oncogene 2003, 22:3395-3406.
42. Supek F., Miñana B., Valcárcel J., Gabaldón T., Lehner B. Synonymous mutations frequently act as driver mutations in human cancers. Cell 2014, 156:1324-1335.
43. Thol F., Kade S., Schlarmann C., Löffeld P., Morgan M., Krauter J., Wlodarski M.W., Kölking B., Wichmann M., Görlich K., et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012, 119:3578-3584.
44. Troy J.D., Atallah E., Geyer J.T., Saber W. Myelodysplastic syndromes in the United States: an update for clinicians. Ann. Med. 2014, 46:283-289.
45. Visconte V., Makishima H., Jankowska A., Szpurka H., Traina F., Jerez A., O'Keefe C., Rogers H.J., Sekeres M.A., Maciejewski J.P., Tiu R.V. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012, 26:542-545.
46. Wahl M.C., Will C.L., Lührmann R. The spliceosome: design principles of a dynamic RNP machine. Cell 2009, 136:701-718.
47. Walter M.J., Shen D., Shao J., Ding L., White B.S., Kandoth C., Miller C.A., Niu B., McLellan M.D., Dees N.D., et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 2013, 27:1275-1282.
48. Woll P.S., Kjällquist U., Chowdhury O., Doolittle H., Wedge D.C., Thongjuea S., Erlandsson R., Ngara M., Anderson K., Deng Q., et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 2014, 25:794-808.
49. Wu S., Romfo C.M., Nilsen T.W., Green M.R. Functional recognition of the 3' splice site AG by the splicing factor U2AF35. Nature 1999, 402:832-835.
50. Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia 1993, 7:144-146.
51. Yoshida K., Sanada M., Shiraishi Y., Nowak D., Nagata Y., Yamamoto R., Sato Y., Sato-Otsubo A., Kon A., Nagasaki M., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478:64-69.
52. Young M.D., Wakefield M.J., Smyth G.K., Oshlack A. Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol. 2010, 11:R14.